Institution Decisions (2)

In Mylan Pharmaceuticals, Inc. v. Gilead Sciences, Inc., IPR2014-00886, Paper 15 (December 17, 2014), the Board declined to institute inter partes review of  claims 1–7, 9–14, and 16–18 of U.S. Patent No. 5,935,946.

In Renesas Electronics Corporation v. ZOND, INC., IPR2014-01066, Paper 17 (December 17, 2014), the Board instituted inter partes review of  claims 18–34 of U.S. Patent No. 6,806,652.

Dispositions (2)

In Groupon, Inc. v. Blue Calypso, LLC, CBM2013-0033, Paper 51 (December 17, 2014), the Board issued a Final Written Decision holding that claims 1-5 of U.S. Patent No. 8,457,670 were unpatentable..

In Groupon, Inc. v. Blue Calypso, LLC, CBM2013-0034, Paper 51 (December 17, 2014), the Board issued a Final Written Decision holding that claims 7-16 and 23-27 were unpatentable, but that claims 1-6 and 17-22 were not.